Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs

Novo Nordisk presented positive Phase 3 trial results for CagriSema, combining an amylin analog with a GLP-1 receptor agonist, showing significant improvements in HbA1c and weight loss. The company also shared Phase 2 data for zenagamtide demonstrating dose-dependent benefits with up to 14.6% body weight reduction. Additionally, Wegovy (semaglutide) tablets surpassed 3 million prescriptions in five months, while semaglutide 2 mg showed advantages over tirzepatide in weight loss outcomes.